

DEPARTMENT OF HEALTH AND HUMAN SERVICES

JAN 23 1998

Reference: BK970040
Product: Medsep PlasmaBag
(EVA Plastic)
Date Received: October 14, 1997
Classification: II

Mr. Edward Nelson
Medsep Corporation
330 Turnbull Canyon Road
City of Industry, CA 91745

Dear Mr. Nelson:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and have determined that the device is substantially equivalent to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments. You may, therefore, market the device, subject to the general controls provisions of the Federal Food, Drug, and Cosmetic Act that include requirements for registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device has been classified into either class II (Special Controls) or class III (Premarket Approval), (see above), it may be subject to the above and additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. In addition, the Food and Drug Administration (FDA) may publish further announcements concerning your device in the Federal Register. Please note that this response to your premarket notification submission does not affect any obligation you might have under the Radiation Control for Health and Safety Act of 1968, or other Federal Laws or regulations.

This letter will allow you to begin marketing your device as described. An FDA finding of substantial equivalence of your device to a legally marketed predicate device permits your device to proceed to the market, but it does not mean that FDA approves your device. Therefore, you

Page 2- Mr. Nelson

may not promote or in any way represent your device or its labeling as being approved by FDA. If you desire specific advice on promotional labeling and advertisement for your device, please contact our Advertising and Promotional Labeling Staff (HFM-202) at (301) 827-3028.

Sincerely,

Jay S. Epstein, M.D.
Director
Office of Blood Research and Review
Center for Biologics
Evaluation and Research

Prepared by SHwangbo(K\510\clearan\BK970040)